Médica Sur S.A.B. de C.V (MEDICAB) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Médica Sur S.A.B. de C.V stock MXN 117, price MXN 54.00, upside +116.5%, quality 83 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 13.65 MXN – 62.50 MXN · fair‑value band 81.85 MXN – 152.00 MXN · the 54.00 MXN price screens below the 116.92 MXN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Médica Sur S.A.B. de C.V in your weekly email
Every Wednesday you see whether Médica Sur S.A.B. de C.V is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Médica Sur, S.A.B. de C.V. operates as a healthcare hospital in Mexico.
Show moreShow less
The company offers angiology, vascular, and endovascular surgery; bariatric surgery; cancer; cardiology; checkup and preventive medicine; children; dental; emergency; endocrinology; gastroenterology, hepatology, and endoscopy; general surgery; geriatric; and gynecology and obstetrics services.
It also provides specialized surgery; neonatology; neurology, neurosurgery, and gamma knife radiosurgery; neurophysiology; nuclear medicine; orthopedic and traumatology; outpatient surgery; plastic surgery; robotic surgery; spine microsurgery; transplant; urology; vascular disease; and imagine and MRI unit services.
In addition, the company offers accommodation; concierge; digital hospital and telemedicine; gourmet; assistance in paperwork and filing procedures with insurer; and tour and transportation services. Further, it provides medical services and diagnosis.
The company was incorporated in 1966 and is based in Mexico City, Mexico. Médica Sur, S.A.B. de C.V. operates as a subsidiary of Neuco, SA de CV.
Stock analysis
Médica Sur S.A.B. de C.V (MEDICAB) currently trades at 54.00 MXN, while our model-based Fair Value estimate is 116.92 MXN, implying the stock looks roughly 54% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 123.65 MXN per share, and 20 of the 26 models we run sit above the 54.00 MXN price.
Bear case: the Dividend Discount group reads lowest at 16.43 MXN, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 81.85 MXN (bear) to 152.00 MXN (bull), the price of 54.00 MXN sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 83/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Médica Sur S.A.B. de C.V reported revenue of 4.8B MXN in FY2025 versus 3.9B MXN in FY2021, a compound +5.2%/yr. Reported net income was 540M MXN in FY2025, compounding −17.3%/yr from FY2021.
Key figures
Market cap 4.9B MXN (≈ $264M) Micro · P/E ratio 24.0 · P/S ratio 2.71 · EPS (TTM) 2.25 MXN · Dividend yield 3.0% · Net margin 11.3% · Return on equity 20.2% · Return on assets (EBIT) 13.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 62 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 117%, MEDICAB screens cheaper than that median.
Fair Value models
Bear81.85 MXNFair Value 116.92 MXNBull152.00 MXN
Price 54.00 MXN · Upside +116.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.5574 MXN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.4%
Start year 2020 (pandemic). Over 10 years: +7.7% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MXN ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MXN: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.5%
Dividend (yield on the price)3.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5.5% vs 21.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 17%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.8%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Mexico: IMF forecast 3.3% a year to 2030, 4.8% from 2016 to 2025) that is about −10.7% a year for the price.
Compare Médica Sur S.A.B. de C.V with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 11/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score83 · Top 25%
Fair Value upside+116.5% · Top 25%
Profitability
Return on equity (12 months)20.2% · Top 25%
Return on assets11.3% · Top 25%
Net margin (12 months)10.9% · Above median
Operating margin (12 months)15.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)−3.2% · Bottom 25%
Dividend yield (12 months)3.0% · Above median
Balance sheet
Debt / equity0.39× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Médica Sur S.A.B. de C.V Fair Value". https://www.fairvalue-calculator.com/stock/MEDICAB
Frequently asked questions
Is Médica Sur S.A.B. de C.V (MEDICAB) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 116.92 MXN versus a price of 54.00 MXN, about +117% upside (undervalued).
What is the fair value of MEDICAB?
Our model-based fair value for Médica Sur S.A.B. de C.V is 116.92 MXN (as of Nov 8, 2026), built from audited fundamentals. The current price: 54.00 MXN.
What is the quality score of MEDICAB?
Médica Sur S.A.B. de C.V has a Quality Score of 83/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Médica Sur S.A.B. de C.V (MEDICAB)?
Our model-based price target is the fair value of 116.92 MXN (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 81.85 MXN, optimistic scenario 152.00 MXN. It is a calculation from audited fundamentals, not an analyst target.
What is the Médica Sur S.A.B. de C.V stock forecast for 2026?
Our models put fair value at 116.92 MXN, about +117% upside versus a price of 54.00 MXN (undervalued). Cautious scenario 81.85 MXN, optimistic scenario 152.00 MXN. The calculation is refreshed regularly with new filings.
What is the revenue of Médica Sur S.A.B. de C.V (MEDICAB)?
Médica Sur S.A.B. de C.V reported trailing-twelve-month revenue of about 4.7B MXN (latest available figure, as of Nov 8, 2026).
Does Médica Sur S.A.B. de C.V pay a dividend?
Médica Sur S.A.B. de C.V currently shows a dividend yield of 2.96% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Médica Sur S.A.B. de C.V (MEDICAB) and when is the ex-dividend date?
Médica Sur S.A.B. de C.V pays a dividend of 1.60 MXN per share a year, a dividend yield of 3.0%. The last ex-dividend date was Jun 2, 2026. A dividend has been paid every year since 2021. The payout ratio is 71.1% of earnings. Free cash flow covers the dividend 5.49 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Médica Sur S.A.B. de C.V (MEDICAB)?
For today's price to be fair in a discounted-cash-flow model, Médica Sur S.A.B. de C.V would have to grow free cash flow by -7.8 % per year for five years (discount rate 13.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.4 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of MEDICAB use?
Our models discount Médica Sur S.A.B. de C.V at 13.5 %: a base by market capitalisation (micro), damped by beta 0.30, country premium for Mexico. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Médica Sur S.A.B. de C.V that is -7.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.5 %) and the same formula as our fair value.
How much growth has Médica Sur S.A.B. de C.V (MEDICAB) delivered so far?
Over the past 5 years revenue at Médica Sur S.A.B. de C.V grew +1.4 % a year. The price currently implies free-cash-flow growth of -7.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Médica Sur S.A.B. de C.V (MEDICAB) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Médica Sur S.A.B. de C.V (-7.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Médica Sur S.A.B. de C.V (MEDICAB)?
The free-cash-flow yield on the price is 16.28 %: that much free cash flow Médica Sur S.A.B. de C.V produces per unit of market value. When it exceeds the discount rate of our models (13.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Médica Sur S.A.B. de C.V (MEDICAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Médica Sur S.A.B. de C.V it is 116.92 MXN per share (as of Nov 8, 2026), against a price of 54.00 MXN. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Médica Sur S.A.B. de C.V stock overvalued or undervalued in 2026?
As of Nov 8, 2026, MEDICAB trades below its calculated fair value: price 54.00 MXN, fair value 116.92 MXN, a gap of about +117% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDICAB?
No. The price is what the market pays today (54.00 MXN); the fair value is what the company's own numbers justify (116.92 MXN). For Médica Sur S.A.B. de C.V the two are 62.92 MXN per share apart. That gap is exactly why we show both numbers side by side.
How much is Médica Sur S.A.B. de C.V worth?
The market values Médica Sur S.A.B. de C.V at about 4.9B MXN (market capitalisation, as of Nov 8, 2026). Per share that is 54.00 MXN; our models calculate a fair value of 116.92 MXN per share.
What do the bullish and bearish scenarios say about MEDICAB?
Our models span a range for Médica Sur S.A.B. de C.V: cautious scenario 81.85 MXN, base 116.92 MXN, optimistic 152.00 MXN per share (as of Nov 8, 2026, price 54.00 MXN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDICAB?
Médica Sur S.A.B. de C.V trades at a price-to-earnings ratio of 24.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 116.92 MXN is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 8.8. Other multiples: P/B 2.0, P/S 1.0, EV/EBITDA 4.7.
How solid is the balance sheet of Médica Sur S.A.B. de C.V (MEDICAB)?
Balance-sheet figures for Médica Sur S.A.B. de C.V (as of Nov 8, 2026): return on equity 20.2%, debt of 0.39 per unit of equity. They feed the Quality Score of 83/100, which measures business quality independently of the share price.
How far is MEDICAB from its 52-week high?
Médica Sur S.A.B. de C.V trades at 54.00 MXN, about 14% below its 52-week high of 62.50 MXN and 4% above the low of 51.90 MXN (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 116.92 MXN is for.
Which stocks are comparable to Médica Sur S.A.B. de C.V?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Médica Sur S.A.B. de C.V stock attractive at the current price?
The data as of Nov 8, 2026: price 54.00 MXN, calculated fair value 116.92 MXN (+117%), Quality Score 83/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDICAB calculated?
We run Médica Sur S.A.B. de C.V through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 116.92 MXN builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Médica Sur S.A.B. de C.V currently trades 54% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Médica Sur S.A.B. de C.V (MEDICAB)?
The closing price on Nov 6, 2026 was 54.00 MXN. Our model-based fair value is 116.92 MXN, about +117% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Médica Sur S.A.B. de C.V right now?
The rarer combination: high quality (83/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (81.85 MXN). The market is more pessimistic than our downside scenario. A fairly wide model range (81.85 MXN to 152.00 MXN) leaves room in how you read the outcome.
Key figures of Médica Sur S.A.B. de C.V
How large is the market capitalisation of Médica Sur S.A.B. de C.V (MEDICAB)?
The market capitalisation of Médica Sur S.A.B. de C.V is 4.9B MXN (≈ $264M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Médica Sur S.A.B. de C.V (MEDICAB)?
The price-to-sales ratio of Médica Sur S.A.B. de C.V is 2.71 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Médica Sur S.A.B. de C.V (MEDICAB)?
Earnings per share at Médica Sur S.A.B. de C.V are 2.25 MXN (price ÷ EPS = P/E 24.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Médica Sur S.A.B. de C.V (MEDICAB)?
The dividend yield of Médica Sur S.A.B. de C.V is 3.0% (payout 71.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Médica Sur S.A.B. de C.V (MEDICAB)?
The net margin of Médica Sur S.A.B. de C.V is 11.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Médica Sur S.A.B. de C.V (MEDICAB)?
The return on equity (ROE) of Médica Sur S.A.B. de C.V is 20.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Médica Sur S.A.B. de C.V (MEDICAB)?
On an EBIT basis the return on assets of Médica Sur S.A.B. de C.V is 13.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Médica Sur S.A.B. de C.V (MEDICAB)?
The operating margin of Médica Sur S.A.B. de C.V is 15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Médica Sur S.A.B. de C.V (MEDICAB)?
Revenue at Médica Sur S.A.B. de C.V is growing −3.2% versus a year earlier (3y avg +7.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Médica Sur S.A.B. de C.V (MEDICAB)?
Earnings per share at Médica Sur S.A.B. de C.V are growing −15.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Médica Sur S.A.B. de C.V (MEDICAB) carry?
The net debt of Médica Sur S.A.B. de C.V is 292M MXN (fiscal year 2023, ≈ 0.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Médica Sur S.A.B. de C.V in the live analysis
One click puts Médica Sur S.A.B. de C.V on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026